Effect of level of hormone-receptor expression on treatment outcomes of "triple-positive" early-stage breast cancer.

Hikmat Abdel-RazeqSara EdailySereen IweirMourad SalamYacob SalehMaher SughayerOsama SalamaRawan MustafaYosra Al-MasriRayan BaterAyat Taqash

Published in: Breast cancer research and treatment (2020)

HER2-positive tumors are not homogeneous; stronger ER/PR co-expression may weaken the beneficial effect of anti-HER2 therapy. Such findings may have potential implication on modifying anti-HER2 treatment based on the strength of HR expression.

Keyphrases

poor prognosis
early stage
stem cells
lymph node
climate change
breast cancer cells
estrogen receptor
sentinel lymph node
replacement therapy